Among 254 GLP-1 receptor agonist users in Saudi Arabia, hair loss emerged as a notable side effect with clear patterns. Mounjaro (tirzepatide) users faced 3.02 times higher odds of hair loss compared to other GLP-1 drugs, while severe hair loss affected 43.4% of Mounjaro and 42.9% of Saxenda users. Women experienced significantly higher rates than men, with married participants showing 9.94 times greater odds of hair loss. This finding adds crucial context to the broader GLP-1 safety profile as these medications gain widespread adoption for weight management. The hair loss appears non-scarring and reversible, suggesting telogen effluvium—a stress-related shedding pattern common with rapid weight loss or metabolic changes. However, the psychological impact could undermine treatment adherence, a critical concern given GLP-1s' proven cardiovascular and metabolic benefits. The differential risk between specific GLP-1 drugs warrants investigation into whether tirzepatide's dual GIP/GLP-1 mechanism contributes to hair loss. While this cross-sectional study from a single region limits generalizability, it identifies an underreported adverse effect that clinicians should discuss proactively with patients, particularly women considering Mounjaro therapy.